Prospective, randomized pilot study of daily consensus interferon alfa (CIFN) and ribavirin for 52 weeks vs. extended duration to 72 weeks based on early virologic response for the initial treatment of difficult-to-treat patients with chronic hepatitis C genotype 1
Phase of Trial: Phase III
Latest Information Update: 07 Aug 2018
At a glance
- Drugs Interferon alfacon-1 (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 25 Feb 2011 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
- 17 Feb 2011 Additional lead trial centres identified as reported by ClinicalTrials.gov.
- 17 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.